Incidence of Dyschromatopsia in Glaucoma

Glaucoma Clinical Trial

Official title:

Incidence of Dyschromatopsia in Glaucoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02966678
• Other study ID #: Dyschromatopsia
• Status: Completed
• Phase: N/A
• First received: November 7, 2016
• Last updated: June 19, 2017
• Start date: November 8, 2016
• Est. completion date: May 30, 2017

Study information

• Verified date: June 2017
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Incidence of dyschromatopsia

Description:

Incidence of dyschromatopsia should be elevated in glaucoma compared to a healthy control population. However, the actual incidence rate is not investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 30, 2017
• Est. primary completion date: May 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• diagnosis of glaucoma

• age between 18 and 99 years old

• best corrected visual acuity(BCVA) > 0.2 (decimal Snellen)

Exclusion Criteria:

• age < 18 yo

• BCVA < 0.2

• known dyschromatopsia

• known corneal disease

• St.p. corneal surgeries

• macula disease

• history of medication use that can influence color vision (e.g. hydroxychloroquine)

Related Conditions & MeSH terms

• Glaucoma

Intervention

Procedure:
• Color Vision Test
Farnsworth Panel D15/Hue test plus Ishihara charts

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of dyschromatopsia	Incidence of dyschromatopsia should be elevated in glaucoma compared to a healthy control population. However, the actual incidence rate is not investigated.	first and only study visit (day 1 of the study)